TCL Archive Long-term Follow-up Shows ADH and ALH Tissue Abnormalities Can Carry Similar Risk January 31, 2014
TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983